Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 1047Neoplasms 821Carcinoma, Non-Small-Cell Lung 806Prostatic Neoplasms 628Colorectal Neoplasms 536Lung Neoplasms 489Neoplasm Metastasis 439Multiple Myeloma 399Leukemia, Myeloid, Acute 392Ovarian Neoplasms 336Pancreatic Neoplasms 318Melanoma 300Squamous Cell Carcinoma of Head and Neck 269Recurrence 260Carcinoma, Hepatocellular 251Glioblastoma 241Brain Neoplasms 240Triple Negative Breast Neoplasms 214Head and Neck Neoplasms 211Carcinoma, Renal Cell 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 205Lymphoma 203Stomach Neoplasms 200Endometrial Neoplasms 191Uterine Cervical Neoplasms 185Glioma 184Sarcoma 183Lymphoma, Non-Hodgkin 183Lymphoma, Large B-Cell, Diffuse 168Hematologic Neoplasms 165

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tumor Lysis Syndrome × 90 days × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡